-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Lowered to $24 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) to Sell 4.08M Shares at $1.226/Share w/Warrants
-
-
-
-
-
-
-
H.C. Wainwright Assumes Capricor Therapeutics (CAPR) at Buy
21,302 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

